Overview

Study of the Bioequivalence and Food Effects of HRX0701 Tablets in Healthy Subjects

Status:
Not yet recruiting
Trial end date:
2022-08-15
Target enrollment:
Participant gender:
Summary
To evaluate the bioequivalence of a single oral dose of HRX0701 tablets and the reference formulations retagliptin phosphate tablets and metformin hydrochloride tablets in healthy subjects in the postprandial state; To evaluate the pharmacokinetic effects of a high-fat diet on retagliptin and metformin after a single oral administration of HRX0701 tablets in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Shandong Suncadia Medicine Co., Ltd.
Treatments:
Metformin